908 Devices Inc. (NASDAQ:MASS) Insider Sells $120,775.82 in Stock

908 Devices Inc. (NASDAQ:MASS - Get Free Report) insider Michael S. Turner sold 16,082 shares of the business's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $7.51, for a total value of $120,775.82. Following the transaction, the insider now directly owns 8,521 shares in the company, valued at $63,992.71. This trade represents a 65.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Michael S. Turner also recently made the following trade(s):

• On Wednesday, June 18th, Michael S. Turner sold 1,373 shares of 908 Devices stock. The shares were sold at an average price of $7.50, for a total value of $10,297.50.

908 Devices Price Performance

MASS stock traded down $0.63 on Friday, reaching $7.34. The company's stock had a trading volume of 2,836,094 shares, compared to its average volume of 1,041,277. 908 Devices Inc. has a 52 week low of $1.81 and a 52 week high of $8.06. The company has a market capitalization of $263.21 million, a P/E ratio of -13.59 and a beta of 0.29. The firm has a fifty day moving average of $5.73 and a two-hundred day moving average of $3.87.

908 Devices (NASDAQ:MASS - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.05. The firm had revenue of $11.78 million for the quarter, compared to analysts' expectations of $11.90 million. 908 Devices had a negative net margin of 28.80% and a negative return on equity of 27.10%. As a group, equities analysts expect that 908 Devices Inc. will post -1.99 EPS for the current fiscal year.

Institutional Trading of 908 Devices

Several institutional investors have recently modified their holdings of MASS. AQR Capital Management LLC bought a new stake in 908 Devices in the first quarter worth about $365,000. AWM Investment Company Inc. grew its position in 908 Devices by 210.6% in the first quarter. AWM Investment Company Inc. now owns 5,199,924 shares of the company's stock worth $23,296,000 after buying an additional 3,526,000 shares during the last quarter. First Light Asset Management LLC acquired a new position in shares of 908 Devices in the 1st quarter worth $7,621,000. PDT Partners LLC acquired a new stake in shares of 908 Devices during the first quarter worth $186,000. Finally, American Century Companies Inc. boosted its position in shares of 908 Devices by 10.8% in the 1st quarter. American Century Companies Inc. now owns 45,814 shares of the company's stock valued at $205,000 after purchasing an additional 4,471 shares during the period. Institutional investors and hedge funds own 88.06% of the company's stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of 908 Devices in a report on Wednesday, June 11th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $5.33.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.